Sökning: "cancer immunotherapy"
Visar resultat 16 - 20 av 168 avhandlingar innehållade orden cancer immunotherapy.
16. Improved cancer survival with use of common antihistamines. Epidemiological studies on the use of H1-antihistamines and survival in cancer
Sammanfattning : Cancer often results from chronic inflammation, and anti-inflammatory medications are therefore potential candidates for drug repurposing for cancer therapy. H2-antihistamines such as cimetidine have long been studied for their promise as cancer medications, but H1-antihistamines have thus far not been studied widely for this purpose. LÄS MER
17. Tumor-targeted superantigens for experimental immunotherapy of human leukemia/lymphoma
Sammanfattning : Bacterial superantigens (SAgs) have the property of stimulating high proportions of T cells expressing certain TCR Vβ sequences. The SAg first binds with high affinity to HLA class II molecules on the target cell and then stimulates the T cell to produce cytokines and to become cytotoxic. LÄS MER
18. Immunological aspects of intratumoral chemotherapy and immunotherapy in malignant brain tumors
Sammanfattning : Advances in surgery, chemo- and radiotherapy have only modestly improved survival rates of malignant brain tumor patients during the last decades. Emerging evidence suggests that an efficient treatment of malignant brain tumors will likely require the management of multiple aspects of tumor pathobiology in order to manipulate features as tumor heterogeneity and tumor immunosuppression. LÄS MER
19. Molecular Characterization of Bladder Cancer Subtypes
Sammanfattning : Bladder cancer is one of the most common malignancies world-wide, and in Sweden approximately 3000 cases are diagnosed annually. Even though bladder cancer is so common there is low public awareness of the disease, and it has historically been less studied compared to other common types of cancer. LÄS MER
20. Translational studies of metastatic melanoma in the era of immunotherapy - from humanized mouse models to clinical trials
Sammanfattning : Immunotherapy with PD-1 inhibitors has transformed the treatment of met-astatic cutaneous mela- noma, and can lead to complete and durable responses in a proportion of patients. However, in around half of the patients, the treatment has little or no effect. LÄS MER
